BVS Bioventus Inc
- Stocks
- Healthcare
- NASDAQ: BVS
Price (delayed)
$7.38
Market cap
$610.79M
P/E Ratio
61.5
Dividend/share
N/A
EPS
$0.12
Enterprise value
$891.21M
Relative Growth:
Rel. Growth:
58
Relative Strength:
Rel. Strength:
38
Relative Valuation:
Rel. Valuation:
71
Relative Profitability:
Rel. Profitability:
69
Bioventus delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The Innovations
Highlights
The company's net income has surged by 119% YoY
Bioventus's EPS has soared by 118% YoY
Key stats
What are the main financial stats of BVS
Market
Valuations
Earnings
Shares outstanding
82.76M
Market cap
$610.79M
Enterprise value
$891.21M
Price to earnings (P/E)
61.5
Price to book (P/B)
3.67
Price to sales (P/S)
0.88
PEG
0.52
EV/EBIT
22.19
EV/EBITDA
10.14
EV/Sales
1.58
Revenue
$563.83M
Gross profit
$382.03M
Operating income
$12.14M
Net income
$7.82M
EBIT
$40.16M
EBITDA
$87.88M
Free cash flow
$53.47M
Per share
Balance sheet
Liquidity
EPS
$0.12
EPS diluted
$0.12
Free cash flow per share
$0.8
Book value per share
$2.01
Revenue per share
$8.42
TBVPS
$4.73
Total assets
$701.59M
Total liabilities
$494.34M
Debt
$322.58M
Equity
$166.1M
Working capital
$119.15M
Debt to equity
1.94
Current ratio
1.74
Quick ratio
1.07
Net debt/EBITDA
3.19
Margins
Efficiency
Dividend
EBITDA margin
15.6%
Gross margin
67.8%
Net margin
1.4%
Operating margin
2.2%
Return on assets
1.1%
Return on equity
5%
Return on invested capital
9.4%
Return on capital employed
7.4%
Return on sales
7.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
BVS stock price
How has the Bioventus stock price performed over time
Intraday
-2.25%
1 week
9.01%
1 month
5.13%
1 year
-35.71%
YTD
-29.71%
QTD
10.31%
Financial performance
How have Bioventus's revenue and profit performed over time
Revenue
$563.83M
Gross profit
$382.03M
Operating income
$12.14M
Net income
$7.82M
Gross margin
67.8%
Net margin
1.4%
Bioventus's operating margin has surged by 121% YoY
The operating income has soared by 120% YoY
BVS's net margin has soared by 119% YoY
The company's net income has surged by 119% YoY
Price vs fundamentals
How does BVS's price correlate with its fundamentals
Growth
What is Bioventus's growth rate over time
Valuation
What is Bioventus stock price valuation
P/E
61.5
P/B
3.67
P/S
0.88
EV/EBIT
22.19
EV/EBITDA
10.14
EV/Sales
1.58
Bioventus's EPS has soared by 118% YoY
BVS's price to book (P/B) is 17% less than its last 4 quarters average of 4.4 but 15% more than its 5-year quarterly average of 3.2
Bioventus's equity has increased by 12% YoY and by 3% from the previous quarter
BVS's P/S is 12% below its 5-year quarterly average of 1.0 and 12% below its last 4 quarters average of 1.0
Efficiency
How efficient is Bioventus business performance
The return on assets has surged by 121% year-on-year
The ROE has soared by 119% year-on-year
The return on invested capital has increased by 18% since the previous quarter
Bioventus's ROS has increased by 15% from the previous quarter
Dividends
What is BVS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for BVS.
Financial health
How did Bioventus financials performed over time
Bioventus's total assets is 42% more than its total liabilities
The quick ratio rose by 37% year-on-year and by 20% since the previous quarter
BVS's current ratio is up by 23% year-on-year and by 18% since the previous quarter
BVS's debt is 94% higher than its equity
BVS's debt to equity is down by 25% year-on-year and by 8% since the previous quarter
BVS's debt is down by 16% YoY and by 5% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.